Summary
Zoetis Inc., a global leader in animal health, officially separated from Pfizer Inc. in early 2013, completing an initial public offering (IPO) of its Class A common stock on the NYSE under the ticker "ZTS." The company's core business revolves around the discovery, development, manufacturing, and commercialization of medicines and vaccines for both livestock and companion animals. Zoetis operates across four geographic segments: the United States, Europe/Africa/Middle East, Canada/Latin America, and Asia/Pacific, with international operations contributing 59% of its total revenues in 2012. The company's product portfolio spans five major categories: anti-infectives, vaccines, parasiticides, medicated feed additives, and other pharmaceutical products. Livestock products represented 65% of 2012 revenues, driven by global population growth and increasing demand for animal protein, while companion animal products accounted for 35%, benefiting from increased pet ownership and longer lifespans for pets. Zoetis emphasizes brand lifecycle development and new product R&D, with a significant investment in innovation. Key financial highlights for 2012 included revenues of $4.336 billion and a net income of $436 million.
Financial Highlights
48 data points| Revenue | $4.34B |
| Cost of Revenue | $1.56B |
| Gross Profit | $2.77B |
| SG&A Expenses | $1.47B |
| Interest Expense | $31.00M |
| Net Income | $436.00M |
| EPS (Basic) | $0.87 |
| EPS (Diluted) | $0.87 |
| Shares Outstanding (Basic) | 500.00M |
| Shares Outstanding (Diluted) | 500.00M |
Key Highlights
- 1Zoetis Inc. completed its IPO on February 6, 2013, listing on the NYSE under the symbol "ZTS," signifying its transition to an independent public company after separating from Pfizer Inc.
- 2The company generated total revenues of $4.336 billion in 2012, with international operations accounting for 59% of this revenue.
- 3Zoetis's product portfolio is diversified across livestock (65% of 2012 revenue) and companion animals (35% of 2012 revenue), with key product categories including anti-infectives, vaccines, parasiticides, and medicated feed additives.
- 4Research and Development (R&D) expenses were $409 million in 2012, reflecting a commitment to innovation through new product development and brand lifecycle management.
- 5The company operates globally across four segments: U.S., Europe/Africa/Middle East, Canada/Latin America, and Asia/Pacific, demonstrating a broad geographic reach.
- 6A significant portion of the company's strategy involves expanding its presence in emerging markets, which contributed 26% of revenues in 2012.
- 7Zoetis incurred substantial debt during the separation, issuing $3.65 billion in senior notes to fund its operations and the separation process.